Ampio begins COVID-19 phase I clinical trial for immunotherapy

By The Science Advisory Board staff writers

June 19, 2020 -- Ampio Pharmaceuticals will begin a phase I clinical trial to evaluate its Ampion drug candidate for treatment of COVID-19 patients who are on supplemental oxygen.

Ampio made the announcement following completion of the U.S. Food and Drug Administration review of the company's investigational new drug application for intravenous treatment with Ampion of COVID-19 patients. Now, the company is cleared to proceed with human trials.

Ampion is based on an immunomodulatory molecule derived from the N-terminus of human serum albumin. The drug has been shown to reduce inflammation by reducing pro-inflammatory cytokine production in T cells. Therefore, Ampion may be effective in interrupting the inflammatory cytokine storm associated with COVID-19 and improve patient outcomes, according to the firm.

Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter